Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance

Results from operations for second quarter 2026 versus second quarter 2025: Revenue: $3.73 billion vs. $3.53 billion, up 5.8% Diluted EPS: $3.64 vs. $2.84, up 28.5% Adjusted EPS: $4.99 vs. $4.35, up 14.9% Raised full-year enterprise revenue growth and adjusted EPS guidance: Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights BURLINGTON, N.C., July 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance. "Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business," said Adam Schechter, Chairman and CEO of Labcorp. "During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders." Labcorp continues to advance its strategic priorities: Lead in specialty testing, with several advancements in Labcorp Oncology: Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity. Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense's primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio. Entered into a clinical trial collaboration with Fox Chase Cancer Center to evaluate Labcorp's Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence. Expanded nationwide access to Roche's FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy TRUQAP. Be a partner of choice for health systems and regional/local laboratories: Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide. Completed the acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio. Completed the acquisition of Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas. Grow Consumer Health : Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source. Introduced Canada's first at-home, self-collection test to measure women's fertility-related hormones and men's testosterone levels. Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health. Shape our future through technology and innovation: Expanded a collaboration with Epic to place 6,500-plus di...